Centcure

CentCure is a biotechnology company focused on developing novel therapeutics that target cancer stem cells (CSCs) to prevent tumor recurrence and metastasis. The company utilizes a proprietary drug discovery platform to identify small molecule inhibitors of critical embryonic signaling pathways, most notably the Wnt/beta-catenin pathway, which are often hijacked by cancer cells. CentCure's lead candidate, CC-101, is being developed for the treatment of solid tumors, including pancreatic and triple-negative breast cancers. By specifically eliminating the self-renewing CSC population, the company aims to overcome chemoresistance and provide more durable clinical responses for patients with aggressive malignancies.